Publications by authors named "Ian Tannock"

Claim this Profile
N
Non-financial conflicts of interest.
Saroj Niraula, Ian F Tannock

Nat Rev Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.
Hans Wildiers, Virginie Adam, Seamus O'Reilly, Josephine Van Cauwenberge, Amal Arahmani, Ian F Tannock

JAMA Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence of published randomised Phase 3 cancer trials to principles proposed by common-sense oncology.
Omar Abdihamid, Bishal Gyawali, Christopher M Booth, Elizabeth A Eisenhauer, Wilma M Hopman, Ian F Tannock

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies for Improving Access to Effective Prostate Cancer Medications (Abiraterone and Enzalutamide) in Low- and Middle-Income Countries (LMICs): A Survey Among Nigerian Health Professionals.
Omolara Fatiregun, Onyeanunam Ekeke, Egbuchilem Chisor-Wabali, John Raphael, Charles Okpani, Ian Tannock

Cancer Control· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conflict of Interest: Moving From Disclosure to Avoidance.
Ian F Tannock, Saroj Niraula

JCO Oncol Pract· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clarifying the role of SONIA: supporting academic evidence on CDK4/6 inhibitor timing.
Avi Petroff, Ian F Tannock, Daniel A Goldstein

Nat Rev Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer.
Ian F Tannock, Madeline Lee Pe, Christopher M Booth, Michael Brundage, Nathan I Cherny

Lancet Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor.
Ian F Tannock, Qamar J Khan, Tito Fojo

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidance for discussants of randomized cancer trials at major meetings.
Elizabeth A Eisenhauer, Omar Abdihamid, Christopher M Booth, Nathan Cherny, Antonio T Fojo, Ian F Tannock

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose optimisation to improve access to effective cancer medicines.
Ian F Tannock, Elisabeth G E de Vries, Antonio Fojo, Marc Buyse, Lorenzo Moja

Lancet Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials.
Bishal Gyawali, Elizabeth A Eisenhauer, Winette van der Graaf, Christopher M Booth, Nathan I Cherny, Ian F Tannock

Lancet Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Putting Patients First: Pragmatic Trials in Gynecologic Oncology.
Laura Hopkins, Mark Clemons, Karen Bemister, Chris Booth, Shannon Kadar, Ian Tannock

Curr Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-inferiority trials: tyranny or good governance? - Authors' reply.
Ian F Tannock, Marc Buyse, Mickael De Backer, Helena Earl, Daniel A Goldstein

Lancet Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.
Tomer Meirson, Jonathan Ofer, Noa Zimhony-Nissim, Avital Bareket-Samish, Gal Markel, Ian Tannock

JAMA Netw Open· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The tyranny of non-inferiority trials.
Ian F Tannock, Marc Buyse, Mickael De Backer, Helena Earl, Daniel A Goldstein

Lancet Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity.
Qian Tan, A M Joshua, M Wang, R G Bristow, B G Wouters, Ian F Tannock

Cancer Chemother Pharmacol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New drug approvals for prostate cancer.
Ian F Tannock

Clin Adv Hematol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
Ian F Tannock, Tomer Meirson, Antonio Fojo

N Engl J Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction notice to "Role of Autophagy as a Survival Mechanism for Hypoxic Cells in Tumors" [Neoplasia 18 (2016) 347- 355/201].
Qian Tan, Marina Wang, Man Yu, Junyan Zhang, Robert G Bristow, Ian F Tannock

Neoplasia· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Lancet Commission on prostate cancer: planning for the surge in cases.
Nicholas D James, Ian Tannock, James N'Dow, Felix Feng, Silke Gillessen

Lancet· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to D.J. Stewart et al.
Christopher M Booth, Elizabeth A Eisenhauer, Bishal Gyawali, Ian F Tannock

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review.
Hannah Louise Bromley, Mohini Varughese, Duncan C Gilbert, Peter Hoskin, Ian F Tannock

BMJ Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending.
Daniel A Goldstein, Leonard B Saltz, Gregory R Pond, Ian F Tannock

BMJ Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs.
Christopher M Booth, Elizabeth A Eisenhauer, Bishal Gyawali, Ian F Tannock

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision medicine for children with cancer.
Ian F Tannock

Lancet Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis